|
MechanismCMV DNA terminase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date08 Nov 2017 |
|
Mechanism1,3-beta-glucan synthase inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date26 Jan 2001 |
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy
Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy
Trial Type : Single arm, prospective trial
Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib)
Treatment Groups : Single arm
Number of trial participants : 30
Non-randomized clinical trial to compare the immunogenicity of revaccination with 23-valent pneumococcal polysaccharide vaccine between healthy elderly and those with diabetes in Korea
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, to Evaluate the Effect of Ertugliflozin on Cardiac Function in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control and Stage B Heart Failure
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic medications including DPP4 inhibitors.
100 Clinical Results associated with MSD Korea Co. Ltd.
0 Patents (Medical) associated with MSD Korea Co. Ltd.
100 Deals associated with MSD Korea Co. Ltd.
100 Translational Medicine associated with MSD Korea Co. Ltd.